AI's transformative role in healthcare and life sciences: Unleashing investment potential
On 19 September we hosted a webinar to discuss how the evolving landscape of AI in healthcare and life sciences is ushering in a new era of opportunities, especially in mergers and acquisitions. We did a deep dive into this groundbraking topic with a panel of AI experts and industry insiders.
Global healthcare is grappling with the effects of aging populations, post-COVID-19 aftermath, climate change impacts, escalating costs and workforce challenges. However, advances in modern and generative AI not only promise to tackle these issues but also enhance patient care and expedite drug discovery. As AI's significance becomes ever-clearer, it's set to catalyze pivotal shifts in both healthcare and healthtech through M&A.JOHN MATTHEWS, ARTIFICIAL INTELLIGENCE SPECIALIST, OAKLINS
If you were unable to attend, you can watch the recording below:
What to expect
- The impact of AI: Understand AI's potential for reshaping patient care, accelerating drug discovery, and revolutionizing clinical diagnosis and care delivery
- M&A in focus: Discover the most promising M&A avenues that are emerging as AI reshapes healthcare and life sciences
- Expert perspectives: Gain firsthand insights from pioneers at the forefront of AI's integration into healthcare and life sciences
Hear these experts share their views about this fast-changing industry:
CEO and Co-Founder, HiLabs
CEO and Founder, Sikka.ai
CEO and Co-Founder, SQREEM Technologies
Member of the Board of Directors, HiLabs
Amit Garg is the CEO and co-founder of HiLabs, where he has leveraged his professional experience in business and product development, operations, consulting and financial analysis, as well as his roots in engineering. Having founded two companies and led them from startups to being successfully acquired, his current professional focus is to simplify data mining in healthcare, so that critical insights can be generated from the sea of complex and unorganized healthcare data. He holds an MBA with distinction in Economics from the Yale University School of Management, and a BS in Industrial Engineering from the Indian Institute of Technology, Roorkee.
Frank Baitman is member of the board of directors at HiLabs and a senior advisor at Oaklins DeSilva+Phillips in New York. He has been a White House Entrepreneur-In-Residence on assignment at the Food and Drug Administration, and initially served as Chief Information Officer for the US Social Security Administration (SSA). In these roles, he successfully launched initiatives to accelerate digital solutions to provide better quality services to citizens while reducing government spending. More recently, he has been Global Head of Digital Health Technology with Genentech/Roche, and Head of Digital Strategy for N-Power Medicine, a startup focused on transforming oncology clinical trials to become more diverse and accelerated.
Ian Chapman-Banks is the CEO and co-founder of SQREEM Technologies. He looks for new ways to predict human behavior, creating AI solutions for governments, banks and pharmaceutical companies. Blending science, coding and business know-how, Ian holds an MBA from Chicago Booth and is a Cambridge student. In the past, he has worked at Apple, Microsoft and Dell, and his business successes include leading a US$4 billion Motorola Asia Pacific venture, delisting a Singapore semiconductor giant for US$4 bullion and listing a Chinese lottery firm at US$500 million.
Vijay Sikka is the CEO and founder of Sikka.ai. Vijay led the Fabs AI group at Intel Corporation in the mid-1990s, then started his first company that became a competitor of Informatica, Hyperion, Cognos and others, and was subsequently acquired. After his second company was also acquired, in 2002, he semi-retired and authored a book. However, inspired by the huge inefficiencies in the US$350 billion dental, veterinary, optometry and retail healthcare markets, he started this latest company. Today it has 139 million patients on its platform and 30,000 practices. The company is EBITDA positive with 98% recurring revenue and growing extremely rapidly.
Elaine Riddell is a managing director at Oaklins DeSilva+Phillips in New York. She has deep operational expertise in the insights industry supporting healthcare and, in particular, life sciences commercialization, on a global basis. Elaine brings an understanding of the disruptive market dynamics shaping these industries and influencing M&A priorities and spending. This highly relevant market knowledge has enabled Oaklins’ insights team to be regularly invited to pitch and to win the majority of this new business.
John Matthews is a managing director at Oaklins DeSilva+Phillips in New York. Coming to investment banking after a career in the technology and management consulting sectors, including a number of years in AI and Data engineering and AI consulting, John has more than 10 years of investment banking experience advising sell-side and buy-side middle-market clients on M&A transactions. Notable AI-related transactions include the sale of Admeta to WideOrbit and the sale of Helixa to Telmar.